OrbiMed Israel BioFund GP Limited Partnership 13D and 13G filings for NOVUS THERAPEUTICS INC:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-05 4:38 pm Unchanged | 2020-12-22 | 13D | NOVUS THERAPEUTICS INC NVUS | OrbiMed Israel BioFund GP Limited Partnership | 73,650 0.500% | 0 (Unchanged) | Filing |
| 2020-12-04 5:12 pm Sale | 2020-12-02 | 13D | NOVUS THERAPEUTICS INC NVUS | OrbiMed Israel BioFund GP Limited Partnership | 73,650 5.100% | -103,200 (-58.35%) | Filing |
| 2020-11-20 4:39 pm Unchanged | 2020-11-16 | 13D | NOVUS THERAPEUTICS INC NVUS | OrbiMed Israel BioFund GP Limited Partnership | 176,850 12.400% | 0 (Unchanged) | Filing |
| 2020-10-13 9:20 pm Purchase | 2020-10-05 | 13D | NOVUS THERAPEUTICS INC NVUS | OrbiMed Israel BioFund GP Limited Partnership | 176,850 14.100% | 176,850 (New Position) | Filing |